Kerecis Expands Fish-skin for Wound Care Lineup
The latest additions aim to support clinicians treating smaller wounds, enhancing flexibility and workflow in surgical wound care.
Kerecis has expanded its SurgiClose Silicone product line by introducing four new sizes designed for use in the operating room. SurgiClose Silicone incorporates intact fish-skin technology with a non-adhesive silicone layer to manage exudate (fluid produced by wounds) and maintain appropriate wound moisture. The new sizes are intended to better address smaller wounds and to offer greater flexibility for clinicians.
The additional sizes include:
Stay Ahead in Regenerative Medicine
Thanks! Your signup has been saved.
– 3×3 cm (with silicone border)
– 5×5 cm (borderless)
– 7×7 cm (with silicone border)
– 10×10 cm (borderless)
According to Kerecis, combining the non-adhesive silicone layer with the fish-skin graft is intended to protect the graft during handling and dressing changes, while also helping care teams maintain an optimal wound environment. The company states that these features are integrated to streamline workflow and support wound healing in surgical care settings.
Fertram Sigurjonsson, Coloplast EVP of Wound and Tissue Repair and Founder and CEO of Kerecis, commented: “We are excited to meet the growing demand for our SurgiClose Silicone product line, which supports care teams to provide an optimal wound environment while protecting the fish-skin graft during handling and dressing changes. Combining these features into one product creates a more efficient, effective workflow, critical to success in surgical care.”
Kerecis develops tissue regeneration solutions using sustainably sourced fish skin and fatty acids. The company’s products are used in wound care, burn treatment, and reconstructive surgery.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
Similar stories
Made Scientific Selected to Manufacture Columbia University’s NOVAKnee, a 3D Printed Knee Replacement Made of Stem Cells and Scaffolds
BioStem Technologies Receives 5 Patents for Placental Allografts
Kangstem Publishes Promising Phase 1 Results for Cord-Blood Derived Stem Cell Therapy in Knee Osteoarthritis, Post-MRI Data Suggest Potential Cartilage Regeneration
Royal Biologics and Jellagen Bringing Jellyfish-Derived Collagen Type Zero to the US Regenerative Medicine MarketEditor’s Picks
Century Therapeutics Reports Sustained Glucose Control With iPSC-Derived Islets in Diabetic Mice, IND Soon
Umbilical Cord Mesenchymal Stem Cell Injections Lower Pain Scores More Than Hyaluronate in 50-Patient Severe Knee Osteoarthritis Trial
Stempeutics Nabs US Patent for Osteoarthritis Treatment Combining Bone Marrow Stem Cells and Hyaluronic Acid
Inside Cellular Intelligence: The Zuck-Backed AI Company That Acquired Novo’s Parkinson’s Cell Therapy
